Earnings Report

JPMorgan reported its first loss during CEO Jamie Dimon's tenure, as the bank suffered under the weight of $9.2 billion in 3Q legal expenses.

Despite posting its best client growth since 2006, FactSet's earnings narrowly trailed forecasts

Europe's largest bank revealed top and bottom-line results that trailed forecasts.

AIG weighed in with 2Q operating results that topped expectations, earning $1.12 a share. The company also unveiled a $1 billion stock buyback.

The card giant reported an 11% jump in processed transactions, outpacing a 5% rise in expenses.

State Street's earnings beat was driven by higher servicing and management fees.

Morgan Stanley revealed adjusted quarterly profits and revenues that beat Wall Street's expectations. The news sent shares up more than 3%.

American Express revealed 2Q earnings of $1.27 a share, topping expectations by a nickel. Revenues of $8.28 billion came in short of estimates.

The ratings firm's earnings rose 8.6% as it continued to benefit from strong corporate-finance results.

Warren Buffett's Berkshire Hathaway revealed 1Q earnings that easily beat expectations on both the top and bottom lines. 

McGraw-Hill beat Street views, as the company benefited from a large gain tied to the sale of its education business.

Shares of the investment bank retreated despite posting adjusted results that exceeded forecasts.

American Express unveiled a stronger than expected 2% rise in profits despite a "slow growth economy," but the card giant's revenue grew less than hoped.

The Wall Street titan's results exceeded expectations thanks to solid investment-banking growth.

The New-York based company posted a 10% jump in net income as investors increasingly turned to the money manager's higher-fee stock funds.

Sherwin-Williams reported a 12% increase in its third-quarter earnings, led by a big sales boost at the company’s paint stores.

AstraZeneca warned that revenue and earnings would drop this year due to the arrival of cheap generic rivals to its cholesterol fighter Crestor.

Bristol-Myers Squibb forecast 2016 earnings slightly above Wall Street estimates.

Amgen Inc. raised its 2015 guidance as the biotechnology company reported that its third-quarter earnings rose 50% on stronger revenue led by Enbrel and other key drugs.

Gilead Sciences Inc said on Tuesday its quarterly net profit rose 32 percent, driven by sales of hepatitis C drugs that beat Wall Street estimates.